All News

The COA Community Oncology Conference will tackle AI, the rollout of bispecifics and CAR T in the community setting, plus reimbursement, radiation oncology, and patient access strategies.

Deuruxolitinib shows consistent efficacy across subgroups and drives early hair regrowth in severe alopecia areata, with gains seen by 8 weeks.

Many MASH cirrhosis trials use histologic endpoints, but a new review finds limited standardization of these outcomes across studies.

Chimeric antigen receptor-based immunotherapies show promise when directed at viral targets, but data are limited.

The benefits of exercise are particularly notable for patients who are dependent upon dialysis, a new review suggests.

The proposed rule on interoperability standards and prior authorization could lead to significant change in CMS.

A French real-world study of 282 patients with CLL identified 2 distinct treatment profiles shaped by age, genetics, and logistics—not trial data alone.

Delgocitinib led to notable improvement by week 4, which may have helped improve longer-term treatment adherence.

Phase 3 TETON-1 trial shows inhaled treprostinil improves FVC in IPF, signaling a potential new antifibrotic option.

A lengthy Ways and Means Committee hearing revealed extensive Medicare system exploitation and ignited partisan debates on fixing it.

Speakers at the NAACOS Spring 2026 Conference illustrated means of using technology in value-based care to implement preventive medicine.

New reports spotlight inequities—from Black maternal mortality to 988’s youth impact—as well as rising cancer risk and gaps in food aid.

Explore 5 FAQs on CDC opioid guidelines, including dosing, tapering, monitoring, and managed care strategies to reduce overdose risk.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Bispecific antibodies are delivering unprecedented response rates in multiple myeloma, offering fast, flexible options alongside CAR T-cell therapy, explains Prerna Mewawalla, MD.

Pediatric care deserts push Medicaid families into costly ED visits; learn how primary care access gaps fuel chronic issues and spending.

Mosunetuzumab, a bispecific, plus polatuzumab vedotin, an antibody-drug conjugate, deliver high response rates in relapsed MCL, potentially enabling outpatient community oncology treatment and wider patient access.

Rani Bansal, MD, explores what's driving the surge in breast cancer in young women and why earlier, risk-based screening matters.

FDA grants lunsotogene parvec-cwha approval for OTOF-related hearing loss, delivering single-dose gene therapy gains and expanding access with free US supply.

Off-the-shelf cema-cel clears MRD at more than triple the rate of observation alone—and may propel a shift to frontline use of CAR T-cell therapy when relapse is hard to detect.

The DEA's 30th biannual collection event arrives April 25, 2026—here's what patients and clinicians need to know.

The FDA approved dupilumab for children aged 2 to 11 years with uncontrolled CSU—the first biologic for this pediatric population.

Nicole A. Caffiero, PharmD, MBA, BCACP, concluded AMCP 2026 by highlighting key themes shaping the specialty drug market.

Parth Desai, MBBS, MD, discusses how clinicians balance liquid biopsy, tissue testing, and fast-start chemo to personalize non–small cell lung cancer treatment.

Cemdisiran offers lower treatment burden for patients living with generalized myasthenia gravis, only needing to be taken every 3 months.

An analysis shows accelerated declines in processing speed, memory, and global cognition years before incident cardiovascular disease.

The Merit-Based Incentive Payment System (MIPS) measure excluded nearly half of all patients undergoing surgery, which could affect surgeon performance.

FDA approves doravirine/islatravir, a once-daily, 2-drug, single-tablet HIV regimen showing noninferior efficacy to standard therapies in suppressed adults.